Mark Elliott Boulding

PTC CLO Mark Elliott Boulding sold 10,462 shares for $822,867.75 in 4 scheduled transactions on 2026-06-17 under 10b5-1 plan.

Mark Elliott Boulding, Executive VP and CLO, executed 4 separate sales totaling 10,462 shares for $822,867.75 on 2026-06-17 under a pre-arranged 10b5-1 trading plan adopted on 2025-09-10, reducing his non-derivative holdings from 115,734 to 105,272 shares. The sales occurred at blended average price of $78.65, while current market price stands at $80.96; however, this is a scheduled, non-discretionary transaction plan, so transaction timing is not a discretionary variable. PTCT's fundamentals show strong revenue growth of +114.5% year-over-year against latest quarterly revenue of $272,551,000.00, though the company reported net loss of $-2,809,000.00 for the latest quarter. Boulding retains 63,888 derivative shares (stock options) across two vehicles, maintaining significant equity exposure to the company.

PTCT CLO Mark Elliott sells 6,618 shares for $511,641.42 across 8 transactions on Jan 6–7

Mark Elliott, Executive Vice President and CLO at PTC Therapeutics, executed 8 separate sales totaling 6,618 shares for $511,641.42 over two trading days (Jan 6–7), with a blended average price of $77.31, reducing his holdings by 5.3% to 117,659 shares. The sell occurs in a mixed fundamental environment: the company posted -14.0% annual revenue decline and was unprofitable on a full-year basis, though the latest quarter showed $211.0M revenue and $15.9M net income. Across his cross-ticker track record, Elliott's prior 20 sales had an average 90-day return of +16.2% with a 10.00% well-timed rate; at PTCT specifically, his 5 prior sales (Oct 2025) did not exhibit well-timed outcomes at the 90-day mark. The current stock price of $76.85 sits 10.9% below the 52-week high of $86.25 and has risen 4.6% over 30 days and 16.0% over 90 days, leaving limited context for material deterioration as a triggering catalyst.

CLO Mark Elliott sells 24,921 shares for $1.6M at $65.75 avg; stock at $63.90 (-2.2% from 52-week high)

Mark Elliott, Executive Vice President and Chief Legal Officer at PTC Therapeutics, executed 11 separate sales on 2025-10-03 and 2025-10-06, totaling 24,921 shares for $1,638,548.63 at a blended average price of $65.75, reducing his holdings from 128,822 shares to 103,901 shares (-19.3%). The stock is currently trading at $63.90, near its 52-week high of $65.37, and has gained 11.6% over 30 days and 31.1% over 90 days. Elliott's cross-ticker track record shows 20 prior open-market sells with an average 90-day return of -1.7% and a 90% well-timed rate, though at PTCT specifically, his 5 prior sales (all from September 2025) do not yet have measurable outcomes. The company is unprofitable with a -$64.8M net loss on $178.9M revenue and is experiencing -14.0% annual revenue decline, though the stock has appreciated significantly in recent months.

PTC Therapeutics CLO Mark Elliott sold 47,249 shares ($2.9M) over two days at $61.18 avg; holds 103.9K post-sale.

Mark Elliott, Executive VP and CLO of PTC Therapeutics, executed 7 separate sales totaling 47,249 shares for $2,890,586.51 across September 11–12, 2025, reducing his holdings by 31.3% to 103,901 shares. The sales occurred at $61.00–$62.09 per share, above the current price of $58.98 and only 3.4% below the 52-week high of $61.09. His prior trades at PTCT show a perfect 5-of-5 well-timed pattern at the 90-day mark, with all sales followed by declines ranging from -19.4% to -24.0% over 30 days. Against this backdrop, the company is unprofitable (annual net income of $-64,849,000.00), experienced -14.0% annual revenue decline, and the stock has appreciated 20.8% over 30 days and 16.0% over 90 days—suggesting recent strong momentum into this sale. The concentrated sale window and timing near recent highs, combined with his established pattern of well-timed exits at this ticker, merit investor attention to near-term price action.

PTCT Executive VP & CLO sold 15,521 shares for $827,232.91 on 2025-03-12, reducing holdings 13.0%

Mark Elliott, Executive VP and CLO at PTC THERAPEUTICS, INC., executed 2 separate sales totaling 15,521 shares for $827,232.91 on 2025-03-12 at blended average price $53.30, reducing his post-transaction holdings to 103,901 shares from 119,422 shares (-13.0%). This sale occurs within days of four prior sales at the same ticker (2025-03-10 and 2025-03-11), suggesting an ongoing pattern of share dispositions. The company context is material: PTCT reported $-106.7M net income on $196.8M quarterly revenue and faces -14.0% annual revenue growth while being unprofitable over its most recent full fiscal year. At the cross-ticker level, Elliott's prior open-market sells showed a 77.78% well-timed rate over 15 transactions with -8.0% average 30-day return, indicating a historical tendency to sell before subsequent declines; however, his prior trades at PTCT remain outcome-indeterminate. The current price of $54.50 is -1.4% from the 52-week high of $55.26, positioning this sale near recent peak valuations.

PTC CLO Mark Elliott sells 75,420 shares for $4,003,304.97; -42.1% of holdings; stock +7.6% (30d), +13.2% (90d)

Mark Elliott, Executive Vice President and CLO, executed 6 separate sales totaling 75,420 shares for $4,003,304.97 across March 10–11, 2025, reducing his stake by 42.1% from 179,321 to 103,901 shares at a blended average price of $53.08. The stock has risen 7.6% over the past 30 days and 13.2% over the past 90 days, while his prior trades at PTCT have been well-timed at the 90-day mark in 3 of 3 prior measurable instances (selling ahead of declines). However, PTCT faces material headwinds: annual revenue declined 14.0% year-over-year, the company was unprofitable with a net loss of $106,654,000.00 on quarterly revenue of $196,786,000.00, and the stock currently sits 3.0% below its 52-week high of $55.26. The scale of this multi-tranched liquidation against the backdrop of negative earnings and revenue contraction warrants close attention to forward guidance and operational developments.

PTC Therapeutics CLO Mark Elliott sells 95,908 shares in 7 transactions for $5,022,334.27; cuts stake by 50.9%.

Mark Elliott, Executive VP and Chief Legal Officer, executed 7 separate sales totaling 95,908 shares for $5,022,334.27 at prices ranging from $52.17 to $54.14 over December 2–3, 2024, reducing his holdings from 188,297 shares to 92,389 shares (−50.9% vs pre-transaction holdings). This is a substantial, multi-tranche divestiture during a period of strong recent momentum: the stock has risen +23.4% over 30 days and +57.8% over 90 days, trading at $49.86 (only −4.2% from its 52-week high of $52.07). Notably, Elliott's prior two open-market sales at PTCT (both on 2023-04-17) also preceded declines, with a 100% well-timed rate at the 90-day mark, suggesting a historical pattern of selling into strength. However, PTCT remains unprofitable (annual net income of $-106,654,000.00), and despite +34.2% annual revenue growth ($196,786,000.00 latest quarter), the unprofitable status and scale of this sale—representing a 50.9% reduction in the insider's stake—merit close attention to whether fundamental concerns align with recent price appreciation.